Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TIOTROPIUM BROMIDE MONOHYDRATE

Form:

4 of 4 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (R03BB) — coverage varies; not interchangeable

  • Umeclidinium (Incruse Ellipta): general benefit

Spiriva Respimat · DIN 02435381 · 2.5mcg/Actuation · Inh Sol-60 Actuation Pk

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Spiriva Respimat · DIN 02435381 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2016-03-30 Health Canada: Marketed since 2014-12-19 · brand SPIRIVA RESPIMAT · ATC R03BB04 TIOTROPIUM BROMIDE · form Solution · route Inhalation · ingredients TIOTROPIUM (TIOTROPIUM BROMIDE MONOHYDRATE) 2.5 MCG/ACT · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Spiriva Respimat: Formulary list price $57.2340/unit (unit not stated in source; not the patient's cost)

Ministry pays: $57.2340 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91971 · Verify on the e-Formulary ↗ (DIN 02435381)

Source record
DIN 02435381: Spiriva Respimat Raw flags: sec3=Y Item: 120808013; group id 216; item number 0393; lccId None; manufacturer id BOE Source form: Inh Sol-60 Actuation Pk; strength: 2.5mcg/Actuation Recorded listing: General benefit Source prices (unrounded): $57.2340; ministry $57.2340 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02435381 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91971 Therapeutic Notes (formulary) Each actuation of Spiriva Respimat contains 2.5mcg of tiotropium, supplied as tiotropium bromide monohydrate.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02435381
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Tiotropium · DIN 02550865 · 18mcg · Inh capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Tiotropium · DIN 02550865 Manufacturer: Apotex Inc.; listing date 2025-02-28 Health Canada: Marketed since 2025-01-23 · brand APO-TIOTROPIUM · ATC R03BB04 TIOTROPIUM BROMIDE · form Capsule · route Inhalation · ingredients TIOTROPIUM (TIOTROPIUM BROMIDE MONOHYDRATE) 18 MCG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Tiotropium: Formulary list price $0.9143/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9143 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103964 · Verify on the e-Formulary ↗ (DIN 02550865)

Source record
DIN 02550865: Apo-Tiotropium Raw flags: sec3=Y Item: 120808009; group id 216; item number 0392; lccId None; manufacturer id APX Source form: Inh Cap; strength: 18mcg Recorded listing: General benefit Source prices (unrounded): $0.9143; ministry $0.9143 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550865 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103964
Interchangeable products
Lupin-Tiotropium · DIN 02537850 · $0.9143 Spiriva · DIN 02246793 · $0.9143
Shortage status: active shortage (reported 2026-04-21, last updated 2026-04-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02550865
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupin-Tiotropium · DIN 02537850 · 18mcg · Inh capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lupin-Tiotropium · DIN 02537850 Manufacturer: Lupin Pharma Canada Limited; listing date 2024-03-28 Health Canada: Marketed since 2023-12-18 · brand LUPIN-TIOTROPIUM · ATC R03BB04 TIOTROPIUM BROMIDE · form Capsule · route Inhalation · ingredients TIOTROPIUM (TIOTROPIUM BROMIDE MONOHYDRATE) 18 MCG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Lupin-Tiotropium: Formulary list price $0.9143/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9143 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102661 · Verify on the e-Formulary ↗ (DIN 02537850)

Source record
DIN 02537850: Lupin-Tiotropium Raw flags: sec3=Y Item: 120808009; group id 216; item number 0392; lccId None; manufacturer id LUP Source form: Inh Cap; strength: 18mcg Recorded listing: General benefit Source prices (unrounded): $0.9143; ministry $0.9143 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02537850 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102661 Therapeutic Notes (formulary) Each tiotropium 18mcg capsule contains 18mcg of tiotropium, equivalent to 22.5mcg of tiotropium bromide monohydrate.
Interchangeable products
Apo-Tiotropium · DIN 02550865 · $0.9143 Spiriva · DIN 02246793 · $0.9143
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02537850
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Spiriva · DIN 02246793 · 18mcg · Inh capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Spiriva · DIN 02246793 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2003-09-04 Health Canada: Marketed since 2002-11-21 · brand SPIRIVA · ATC R03BB04 TIOTROPIUM BROMIDE · form Capsule · route Inhalation · ingredients TIOTROPIUM (TIOTROPIUM BROMIDE MONOHYDRATE) 18 MCG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Spiriva: Formulary list price $0.9143/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9143 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70993 · Verify on the e-Formulary ↗ (DIN 02246793)

Source record
DIN 02246793: Spiriva Raw flags: sec3=Y Item: 120808009; group id 216; item number 0392; lccId None; manufacturer id BOE Source form: Inh Cap; strength: 18mcg Recorded listing: General benefit Source prices (unrounded): $0.9143; ministry $0.9143 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246793 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70993 Therapeutic Notes (formulary) Each tiotropium 18mcg capsule contains 18mcg of tiotropium, equivalent to 22.5mcg of tiotropium bromide monohydrate.
Interchangeable products
Apo-Tiotropium · DIN 02550865 · $0.9143 Lupin-Tiotropium · DIN 02537850 · $0.9143
Shortage status: resolved shortage (ended 2026-02-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246793
Shortage record checked 2026-09-13T08:10:21.292534+00:00

TIOTROPIUM BROMIDE MONOHYDRATE & OLODATEROL HYDROCHLORIDE

All products: Limited Use (codes 459)

Other products in the same Health Canada class (R03BB) — coverage varies; not interchangeable

  • Umeclidinium (Incruse Ellipta): general benefit

Inspiolto Respimat · DIN 02441888 · 2.5mcg & 2.5mcg/Actuation · Inh Sol-60 Actuation Pk

Limited Use — Reason for Use code 459 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 459 required
Write on scriptLU code 459 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 459
Reason for Use code 459 For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)). Coverage limit: LU Authorization Period: Indefinite Coverage limit: COPD disease severity is based on spirometry, symptoms and disability (see classification tables below). Classification COPD Stages - Symptoms and disability: Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill. Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure Classification by impairment of lung function: COPD stage and spirometry (post bronchodilator) FEV1 predicted: Mild: Greater than or equal to 80 percent Moderate: 50 to 79 percent Severe: 30 to 49 percent Very severe: Less than 30 percent
No interchangeable product listed in the Ontario extract
Inspiolto Respimat · DIN 02441888 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2016-03-30 Health Canada: Marketed since 2015-05-29 · brand INSPIOLTO RESPIMAT · ATC R03AL06 OLODATEROL AND TIOTROPIUM BROMIDE, R03AL06 OLODATEROL AND TIOTROPIUM BROMIDE · form Solution · route Inhalation · ingredients OLODATEROL (OLODATEROL HYDROCHLORIDE) 2.5 MCG/ACT, TIOTROPIUM (TIOTROPIUM BROMIDE MONOHYDRATE) 2.5 MCG/ACT · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Inspiolto Respimat: Formulary list price $67.1580/unit (unit not stated in source; not the patient's cost)

Ministry pays: $67.1580 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92626 · Verify on the e-Formulary ↗ (DIN 02441888)

Source record
DIN 02441888: Inspiolto Respimat Raw flags: sec12=Y, sec3=Y Item: 120808012; group id 217; item number 0394; lccId 00263; manufacturer id BOE Source form: Inh Sol-60 Actuation Pk; strength: 2.5mcg & 2.5mcg/Actuation Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $67.1580; ministry $67.1580 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02441888 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92626 Therapeutic Notes (formulary) Each actuation of Inspiotto Respimat contains 2.5mcg of tiotropium, supplied as tiotropium bromide monohydrate, and 2.5mcg of olodaterol, supplied as olodaterol hydrochloride.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02441888
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (12:08:08 Antimuscarinics/Antispasmodics) and how they are covered

Matched class: 12:08:08 Antimuscarinics/Antispasmodics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: UMECLIDINIUM 12:08:08 Antimuscarinics/Antispasmodics

UMECLIDINIUM

· 1 products · General benefit · strengths: 62.5mcg · Blister Pd Inh-30 Dose Pk

GLYCOPYRROLATE

· 10 products · Limited Use, codes 481 (7), Listed, not a benefit (3) · strengths: 0.2mg/mL, 0.4mg/2mL, 4mg/20mL · Inj Sol, Inj Sol (Preservative Free), Inj Sol (With Preservative)

HYOSCINE BUTYLBROMIDE

· 1 products · Limited Use, codes 481 · strengths: 20mg/mL · Inj Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:08:08
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: obstructive pulmonary disease
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, GLYCOPYRRONIUM BROMIDE, UMECLIDINIUM ACLIDINIUM BROMIDE · General benefit INDICATIONS AND CLINICAL USE TUDORZA GENUAIR (aclidinium bromide) is indicated as a long-term maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00067375.PDF; date not captured; DIN 02409720; fetched 2026-09-10 Product monograph ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 459 INDICATIONS AND CLINICAL USE DUAKLIR GENUAIR (aclidinium bromide/formoterol fumarate dihydrate) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA) indicated as a long-term maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. PM: https://pdf.hres.ca/dpd_pm/00067361.PDF; date not captured; DIN 02439530; fetched 2026-09-10 Product monograph FLUTICASONE FUROATE & VILANTEROL · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) INDICATIONS AND CLINICAL USE COPD BREO ELLIPTA (fluticasone furoate/vilanterol) 100/25 mcg is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations. PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10 Product monograph GLYCOPYRRONIUM BROMIDE · General benefit 1 INDICATIONS SEEBRI ® BREEZHALER ® (glycopyrronium bromide) is indicated as a long-term once-daily maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00067963.PDF; date October 16, 2012; DIN 02394936; fetched 2026-09-10 Product monograph INDACATEROL & GLYCOPYRRONIUM · Limited Use, codes 459 1 INDICATIONS ULTIBRO BREEZHALER (indacaterol maleate and glycopyrronium bromide) is a combination of a long- acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and for the reduction of exacerbations of COPD in patients with a history of exacerbations. PM: https://pdf.hres.ca/dpd_pm/00072513.PDF; date Dec 23, 2013; DIN 02418282; fetched 2026-09-10 Product monograph UMECLIDINIUM · General benefit 1 INDICATIONS INCRUSE ELLIPTA (umeclidinium) is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00072581.PDF; date April 8, 2014; DIN 02423596; fetched 2026-09-10 Product monograph UMECLIDINIUM & VILANTEROL · Limited Use, codes 459 1 INDICATIONS ANORO ELLIPTA (umeclidinium/vilanterol) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA) indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00069868.PDF; date March 14, 2014; DIN 02418401; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS SPIRIVA (tiotropium bromide monohydrate) is indicated for:  long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. SPIRIVA is not indicated as rescue medication for the relief of acute bronchospasm in COPD. 1.1 Pediatrics  Pediatrics (< 18 years of age): Safety and effectiveness of SPIRIVA in patients less than 18 years of age were not studied. 1.2 Geriatrics  Geriatrics (≥ 65 years of age): No dose adjustment is required for patients 65 years of age or older. https://pdf.hres.ca/dpd_pm/00065560.PDF PM date: NOV 20, 2002 Source product: SPIRIVA; DIN 02246793; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE INSPIOLTO RESPIMAT (tiotropium bromide monohydrate and olodaterol hydrochloride) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA) indicated for the long term, once daily maintenance bronchodilator treatment of airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema. INSPIOLTO RESPIMAT is not indicated for the relief of acute deterioration of COPD. INSPIOLTO RESPIMAT is not indicated for asthma use. The safety and effectiveness of INSPIOLTO RESPIMAT in asthma have not been established (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS, General). Geriatrics (> 65 years of age): Elderly patients can use INSPIOLTO RESPIMAT at the recommended dose. No dosage adjustment is required. Pediatrics (< 18 years of age): INSPIOLTO RESPIMAT should not be used in patients under 18 years of age. Inspiolto® Respimat ® Product Monograph Page 3 of 50 https://pdf.hres.ca/dpd_pm/00054220.PDF PM date: November 14, 2019 Source product: INSPIOLTO RESPIMAT; DIN 02441888; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Tiotropium · DIN 02550865 Shortage status: active shortage (reported 2026-04-21, last updated 2026-04-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02550865

Check this DIN again